Chartwell Investment Partners, LLC Fate Therapeutics Inc Transaction History

Chartwell Investment Partners, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 26, 2022	SELL	$29.67 - $60.28 $347,376 - $705,758	-11,708 Closed	0 $0
Q4 2021 Feb 15, 2022	SELL	$47.84 - $64.34 $9,902 - $13,318	-207 Reduced 1.74%	11,708 $685,000
Q2 2021 Jul 19, 2021	BUY	$67.25 - $92.52 $424,011 - $583,338	6,305 Added 112.39%	11,915 $1.03 Million
Q1 2021 May 03, 2021	SELL	$72.16 - $117.4 $21,648 - $35,220	-300 Reduced 5.08%	5,610 $463,000
Q4 2020 Feb 09, 2021	BUY	$38.09 - $100.95 $225,111 - $596,614	5,910 New	5,910 $537,000
Q3 2018 Nov 08, 2018	SELL	$8.75 - $16.29 $676,410 - $1.26 Million	-77,304 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$9.16 - $13.48 $708,104 - $1.04 Million	77,304 New	77,304 $877,000
Q1 2018 May 08, 2018	SELL	$6.3 - $13.77 $505,556 - $1.11 Million	-80,247 Closed	0 $0
Q1 2018 May 08, 2018	BUY	$6.3 - $13.77 $505,556 - $1.11 Million	80,247 New	80,247 $783,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $163M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Chartwell Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Chartwell Investment Partners, LLC with notifications on news.